Morgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Incyte (NASDAQ:INCY) and lowers the price target from $74 to $64.
November 01, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Incyte and lowered the price target from $74 to $64.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Incyte's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100